Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al-Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna-Maria Fink, Sandra Robrecht, Olga Samoylova, Anna M Liberati, Javier Pinilla-Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura M Fogliatto, Carsten U Niemann, Robert Weinkove, Sue Robinson, Thomas J Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer

Open source

DOI: 10.1016/s1470-2045(20)30443-5
Published: 2020-09
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-20-30443-5,
  title = {Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial},
  author = {Othman Al-Sawaf and Can Zhang and Maneesh Tandon and Arijit Sinha and Anna-Maria Fink and Sandra Robrecht and Olga Samoylova and Anna M Liberati and Javier Pinilla-Ibarz and Stephen Opat and Liliya Sivcheva and Katell Le Dû and Laura M Fogliatto and Carsten U Niemann and Robert Weinkove and Sue Robinson and Thomas J Kipps and Eugen Tausch and William Schary and Matthias Ritgen and Clemens-Martin Wendtner and Karl-Anton Kreuzer and Barbara Eichhorst and Stephan Stilgenbauer and Michael Hallek and Kirsten Fischer},
  year = {2020},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(20)30443-5},
  url = {https://doi.org/10.1016/s1470-2045(20)30443-5}
}

RIS

TY  - JOUR
TI  - Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
AU  - Othman Al-Sawaf
AU  - Can Zhang
AU  - Maneesh Tandon
AU  - Arijit Sinha
AU  - Anna-Maria Fink
AU  - Sandra Robrecht
AU  - Olga Samoylova
AU  - Anna M Liberati
AU  - Javier Pinilla-Ibarz
AU  - Stephen Opat
AU  - Liliya Sivcheva
AU  - Katell Le Dû
AU  - Laura M Fogliatto
AU  - Carsten U Niemann
AU  - Robert Weinkove
AU  - Sue Robinson
AU  - Thomas J Kipps
AU  - Eugen Tausch
AU  - William Schary
AU  - Matthias Ritgen
AU  - Clemens-Martin Wendtner
AU  - Karl-Anton Kreuzer
AU  - Barbara Eichhorst
AU  - Stephan Stilgenbauer
AU  - Michael Hallek
AU  - Kirsten Fischer
PY  - 2020
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(20)30443-5
UR  - https://doi.org/10.1016/s1470-2045(20)30443-5
ER  -

APA

Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A., Robrecht, S., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Dû, K. L., Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Tausch, E., Schary, W., Ritgen, M., Wendtner, C., Kreuzer, K., Eichhorst, B., Stilgenbauer, S., Hallek, M., & Fischer, K. (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30443-5

Source records

crossref · retrieved 2026-09-25T20:32:45.477Z